Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shell Company - Classic PUMP & DUMP!
20/20 Review of Regen Biopharma - An Up & Coming Player In The Immuno-Oncology Market
https://pennystocks.today/rgbp-stock-the-biotech-stock-to-look-out-for-in-2022/
Specializing in the treatment of cancer and autoimmune diseases, Regen BioPharma Inc. (OTC: RGBP) and (OTC: RGBPP) is a biotech penny stock making notable contributions to the industry and particularly the immunology and immunotherapy space. Despite trading at a dip, RGBP stock has a number of upcoming catalysts which could send it to new highs in the long-term.
Catalysts
At the forefront of the biotech industry, Regen BioPharma’s portfolio of patents has allowed the company to make notable leaps. Earlier this year, the company obtained a license entitling it to exclusive rights for developing and marketing IP for the treatment of pancreatic cancer. This prompted a runup of 1076% for RGBPP (preferred stock) and 2723% for RGBP (common stock) in April.
The company obtained two other patents by the second quarter of 2021, the first one for using T regulatory cells in the treatment of arthritis and autoimmunity. Currently, testing this cell treatment on animals, Regen BioPharma will have a lengthy review process with the FDA before it becomes marketable. However, the global market for Rheumatoid Arthritis drugs alone was forecast to reach $36.11 billion by 2027. If this treatment proves successful, the ROI could be significant.
In October, RGBP obtained yet another patent for its “Universal Donor Checkpoint Inhibitor Silenced/Gene Edited Cord Blood Killer Cells” which covers RGBP’s invention of treatments that induce an “anticancer” response in patients. It’s therapeutic use can trigger an antitumor immune response from the body which has the potential to be revolutionary for the company.
Another patent was granted to RGBP for Antigen specific mRNA cellular cancer vaccines which could be a lucrative patent considering that mRNA is currently a leading treatment in the biotech industry. With this in mind, the company has been exploring ways to capitalize on its patents leading it to give a Scope of Work order to Biotech Research Group in October in an attempt to strategize methods of commercializing its NR2F6 intellectual property. This is important because the NR2F6 nuclear receptor was identified as a potential immune cell inhibitor that can help trigger the immune system to fight cancer as well as autoimmunity diseases and chronic inflammation.
Meanwhile, the company seems to be building on two successful deals with Oncology Pharma from earlier this year as it sets out to commercialize its research. RBGP made these agreements with Oncology Pharma giving the latter the exclusive right to develop and commercialize IP related to the treatment of cancer. In October, RGBP agreed to provide Oncology Pharma with intellectual property related to the mRNA used to treat pancreatic cancer as well. In exchange, RGBP received a fee of $55,000, and will take 5% royalties in net sales as well as 10% of all consideration from sublicensees.
At the same time, the company has been updating its filings in preparation for up-listing to the OTCQB. Its decision to opt for full reporting status has fueled speculation of a possible Big Pharma buyout that would require this level of detailed reporting. This has led some to speculate RGBP could be an acquisition target for Oncology Pharma considering their successful relationship. But Precigen was also rumored to be a buyout candidate due to Precigen’s CEO – Helen Sabzevari – former role on RGBP’s Scientific Advisory Board. But many are hopeful that Eli Lilly is the potential target since it has maintained a working relationship with RGBP for over 5 years.
Beginning in 2016 with a definitive agreement allowing Regen to receive compounds from Lilly for drug discovery purposes and to exchange information of mutual interest, the two companies have since covered a lot of ground together. In 2017, Eli Lilly’s former Executive led RGBP’s newly formed Business Advisory Board. Because there is a Drug Discovery Pact between both parties, some are wondering if RGBP may be a target for the massive company.
RGBP’s CEO –Dr. David Koos – appears very bullish, saying “Companion diagnostics in precision oncology is where the future of cancer treatment is heading.” He went on to explain that the global cancer diagnostics market is growing rapidly – increasing from $168 billion in 2020 to a predicted valuation of $280 billion by 2028.
It also seems RGBP has been cleaning house after settling convertible notes equivalent to $1,023,454. But the company has evidently been on a campaign to pay off its debts for several months now, paying off $539,392 in other fees through the issuance of roughly 706.4 million common shares and 23.7 million Series A Preferred shares. This appears to have nearly erased the company’s debt except for a remaining $1,340,621 in convertible notes.
Shareholders have been re-energized with the release of RGBP’s new 10-K which shows that the company’s CEO – David Koos – is still holding Common 3.18 million common stock shares, 38% of A Preferred shares, and 26.14% of M Preferred shares as well as 100% of AA Preferred and NC preferred shares. His heavy investment in the company is definitely a bullish sign that has helped offset the dip following an announcement from Pomerantz Law Firm that it is investigating claims on behalf of Regen BioPharma, Inc.’s shareholders.
The reason for the firm’s investigation appears to be that the previously issued Balance Sheet, Statement of Operations, Statement of Shareholders Equity and Statement of Cash Flow for period ending June 30, 2021 “should not be relied upon” because it had determined that the $1,905,000 in revenue recognized from license grant to an unrelated third party should be recognized over the 15 year term of the license.
While this news shook some shareholders, most have been buoyed by the results of the company’s latest quarterly report which is unaffected by this investigation. Furthermore, Pomerantz Law Firm is not seen as a highly reputable firm having filed numerous lawsuits on similar charges.
In any case, according to RGBP’s financial document the company has $727,162 cash on hand and total assets amounting to $1.2 million. The company also recorded $171,194 in revenue but is operating at a loss of $6.7 million as is typical of biotech companies which move on binary events.
Building on its mRNA patent, RGBP has been developing a program to commercialize its anti-cancer vaccine. In the program’s first phase, RGBP will perform initial pre-clinical studies required for FDA submission.
This technology uses modified mRNA molecules to target the Survivin protein which blocks the death of cancer cells. Following this, the molecules are infused into cancer patients’ blood where they destroy cancer cells. Considering that similar trials on this subject are ongoing around the world, RGBP believes that this would support its anticipated FDA submission.
To facilitate this, RGBP will partner with Oncology Pharma to accelerate the development of RGBP’s patented mRNA vaccines. According to this partnership, RGBP will provide its scientific background, laboratories, and the modified mRNAs required for the completion of the studies while Oncology Pharma will finance the studies.
Although both companies are confident they will close this partnership, it is dependent on the execution of a number of definitive agreements and finances.
In addition to this, RGBP plans to speed up the clinical development of its NR2F6 therapies by combining its modified mRNA technology with its siRNA IP. RGBP has already filed an Investigational New Drug Application with the FDA for its new drug – tCellVax.
This new drug stimulates the immune cells to eliminate cancer cells by employing RGBP’s siRNA technology to silence NR2F6 activity in the immune system. In light of this, RGBP has contracted Dyo-Biotechnologies to assist the company in advancing this new technology.
On that note, many investors are bullish on this development given the experience Dyo’s management has in the biotech industry. With over 25 years of experience, Dyo is led by Dr. Harry Lander – well known for having relationships with several small and large biotechnology companies. Through these relationships, RGBP has the potential to grow its business financially and scientifically.
With RGBP receiving a patent for its small molecule modulators, Koos believes that “by adding our new mRNA intellectual property to tCellVax we can simplify its administration to patients and thus create a much more marketable drug” and that “An RNA-based checkpoint inhibitor will be a first-in-class drug”. In light of this, RGBP’s new drug could revolutionize cancer treatments after receiving approval from the FDA.
After partnering with Oncology Pharma to finance the acceleration of its mRNA vaccine, RGBP decided to cancel its acquisition of Canary Oncoceutics. In light of this, many investors are relieved that RGBP will no longer have to raise the $50 million stated in the LOI. Investors are also speculating that the termination of this acquisition could be due to the company pursuing a buyout deal.
Recently, RGBP provided an update to its shareholders regarding the company’s share structure. Based on this update, the company increased its authorized shares to 5.8 billion – due to an obligation to a note holder. However, RGBP assured its shareholders that the additional shares have not been issued.
Given that medical treatments have a long timeline before receiving approval from the FDA, RGBP stock has the potential to be a profitable long-term hold. However, recently many investors are feeling bullish about the company’s future after RGBP began its pre-clinical trials for a Myelodysplastic syndromes drug in March. As the company provides updates on the trials, RGBP could see an uptick with positive news.
Very Dangerous City
....you may never come back
Well Said!
100% CORRECT!
Here's something that hasn't been mentioned that needs to be said
IF the source of the $50M funding for this Triangular Acquisition is a Big Pharma (BP), it will represent a strategic move on several levels:
#1- first shot at developing any of Regen's IPs
#2- diversification into Precision Oncology: presently a $168B Global Market projected to skyrocket to $280B by 2028. This represents Disruptive Biotechnology that will define the future of ALL cancer diagnosis & treatment methods keeping in mind that the BP will own Canary via a Reverse Acquisition (i.e. a private company acquired by a public company).
#3- breaking into the mRNA Cancer Vaccine Market via Regen's NR2F6 IP.
#4- An indirect working relationship with Weill-Cornell that functions in part for fast tracking Big Pharma IPs to commercialization (see #2 Link below). This is in-sync with their rapid acceleration of therapeutics "Bench-to-Bedside" directive by harnessing innovative scientific approaches including artificial intelligence, translational cellular therapy, regenerative medicine, etc. Canary fits right into this directive with its Precision Oncology Diagnostic Platform. (see links below a MUST READ!)
https://news.weill.cornell.edu/news/2021/09/ready-to-launch-weill-cornell-has-an-ambitious-new-plan-to-change-medicine-0
(Weill-Cornell Partnerships with Big Pharmas to speed drug discovery)
https://news.weill.cornell.edu/news/2012/06/weill-cornell-partners-with-pharmaceutical-companies-and-academic-researchers-to-speed-tuberculosis
An important directive of ALL BPs is Market Diversification & Dominance that places them ahead of their fierce competition. This is what Gilead Sciences did when they acquired Kite Pharma in 2017 for $12B motivated in part by Kite's mRNA Cancer Vaccine IP when little was known about mRNA Vaccines at that time.
In regard to this, it's interesting to note that 2017 was the general time frame when Eli Lilly paid $100M to partner with Curevac to develop an mRNA Cancer Vaccine that failed in 2020 due to Curevac's faulty research data. I'm willing to bet Lilly is going to re-attempt this pursuit that might land them back in partnership with Regen. After all they have had prior collaborative arrangements with Regen on the NR2F6 IP they hold partial claim on that's the basis for an mRNA Cancer Vaccine. Is it making sense yet??
The BP that acquires Canary will have in-direct partnership with Regen due to owning its subsidiary. There are many advantages to this arrangement, i.e. additional funding for IP development, etc.
Like I've said before, Koos is an absolute genius and I believe he's going to make good on this Acquisition. Why? It was brilliantly planned with key players and innovative Biotechnology combined!
Lastly, I don't see any reason why this Acquisition won't be funded for reason there are vast strategic Market implications for any Big Pharma that springs for the $50M keeping in mind that this amount of money to ANY BP is "chump change" relative to their typical Multi-Billion Market Cap. i.e. Gilead Sciences $86B, Eli Lilly $226B.
OPINION ONLY
All feedback welcome with your personal perspectives.
Be well and prosper...
We're At A Major Cross Road - A Fundamental Shift in RGBP's Market Profile
I agree with your insight perspective
Based on consensus among Stockwitz posters this week it appears Eli Lilly is the #1 Pick for the $50 Million Partnership Acquisition Funding!
Seems reasonable to me seeing Lilly took a shot at co-developing an mRNA Cancer Vaccine with Curevac back in 2017 that cost them $100 Million up front for the partnership deal, but then it abruptly ended in June 2020 due to Curevac having faulty research data.
Lilly's $100M went up in smoke so no doubt they're likely to return to Regen where it all began via their collaborative efforts on NR2F6, the basis for an mRNA Cancer Vaccine. This is only speculation of course but it would make sense based on the history Lilly has with Regen which is undeniable!
Ironically Lilly shares IP claim on that molecule with Regen so it seems like a natural fit! Even one of Lilly's Senior Executives, Jean-Pierre Million, served as Chairman of Regen's Scientific Advisory Board some years ago for evaluating, developing, and licensing Regen's IP including NR2F6. By the Way Million owns at least 7M Shares of RGBP Stock which was disclosed in one of Regen's SEC filings.
So yes, I definitely agree with your perspective.
Based on all of Koos efforts throughout 2021, with over 40 SEC Filings, Patent re-activations, etc, he has succeeded in positioning RGBP for significant growth moving forward.
Any major partnership like the one currently pending for the $50M Acquisition should be the icing on the cake that moves the PPS IN AN UPWARD TREND. Additional developments like Regen's INDs entering Clinical Trials and any positive results of those trials is what is needed long term.
Be well and prosper...
AMEN!
You Nailed it BIG TIME!
Well said and I applaud you for your keen insight.
I can tell you in no uncertain terms as a Clinical Trials Physician the following:
1). The Magnitude of funding Koos is seeking for the Canary Acquisition of Weill-Cornell's technology that makes sense, can ONLY come from a Big Pharma. There are very few sources someone can turn to for funding anywhere close to this amount of money unless it's a major corporation.
2). You're right again that IF this deal doesn't go through, it would result in the perception that Regen and Koos himself are essentially back to square one and that would cast a shadow over the company's market perception and future. It would take A LOT to recover from, so his reputation is definitely on the line like you said.
3). It's very clear that the deal presently on the table for the $50M funding is a Big Pharma which is consistent with Koos 8/27/21 8K where he suggested an Acquisition/Buy Out, only the structuring is "in direct", where the funding is for acquiring the Technology of Weill-Cornell via Regen's new wholly owned subsidiary Canary, and Patent licensing or ownership by the Big Pharma partner, but nevertheless Koos is the principal.
4). It's important to clarify the players and what their roles are. They are #1 Regen; #2 Canary; #3 Weill-Cornell, and #4 an unidentified Big Pharma.
The Big Pharma provides the funding that centers on developing a limited selection of Regen's Innovative Patents, and those Patents are the subject of fast track development into various therapeutics for commercialization via the efforts of Weill-Cornell who holds the technology & expertise for that to happen AND they have a well established history of many Big Pharmas utilizing their services which is similar to the role of a Contract Research Organization (CRO).
Weill-Cornell is functionally playing the role of a CRO as they have the technology, manpower, and capacity to make it all happen, and ALL of this is what Big Pharmas now-a-days hire CROs for because they don't want the labor intensiveness and enormous manpower requirement and cost to bring something like this In-House, and no doubt that was a major deal point between Koos and the Big Pharma presently at the table with him.
No doubt whoever the Big Pharma player is, they wanted a highly qualified source that has the ability to bring Regen's Patents to commercialization which Weill-Cornell has an well established reputation for with many Big Pharmas, and they also have the financial backing of The Bill & Melinda Gates Foundation and no doubt dozens of other financial contributors.
Canary,although they have precision oncology testing platforms that will complement existing cancer genomic testing on patient's tumors allowing physicians to select therapeutics generated through genomic testing down to specific drug combinations, Canary's revolutionary approach to precision oncology is enabled by technology they seek to license from Weill-Cornell as a subsidiary of Regen, and several of Regent's Patents will be included in the drug discovery process upon conversion into a therapeutic.
It should all make sense now! I may be overlooking something but these are the key pieces to the puzzle.
20/20 on Weill-Cornell
https://news.weill.cornell.edu/news/2012/06/weill-cornell-partners-with-pharmaceutical-companies-and-academic-researchers-to-speed-tuberculosis
So for this deal to do down, it will require the $50M from the Big Pharma player presently at the table who no doubt wants a high probability of certainty that the Patents they're acquiring or licensing from Regen included in the $50M funding deal, will enter the Weill-Cornell fast track incubator program for I.P. development into therapeutics via the "perfect marriage" between Canary & Weill-Cornell which the Big Pharma will have a financial stake in, the details of which are unknown at this point.
So essentially it will cost the Big Pharma in bed with Regen far less to fund the development of selected Patents in Regen's portfolio, than to buy Regen outright with all its Patents, and simultaneously acquire the technology from Weill-Cornell for Canary's platforms, which is better for both parties. Regen is then able to continue to license its other Patents with several Big Pharmas while systematically commercializing their Patents via Weill-Cornell's fast track program.
If this deal goes through, what needs to be recognized about it all is it represents a Big Pharma Partnership and whoever that Big Pharma is, at some point they will be licensing and/or claim ownership of those Patents in development at Weill-Cornell.
Like I've said many times before, "Dr. Koos is a genius."
Be well and prosper...
Thanks! That's what I thought as well!
Thank you to all who responded to my question!
Have a blessed 2022
P.S. Does anyone here know how to email OTC Markets??
RGBP's Float
Can anyone here confirm what the current 2022 Float is for RGBP?
OTC Markets shows it at 213.89M
iHub it shows 213.90M.
There are some who have suggested that the Float is the same as the Unrestricted Shares shown on OTC Markets as 4.5B
Does anyone care to elaborate on this??
Thank you
WRONG!
No it was NOT Koos who ran RGBP into the ground, it was the joker who took over when he left which is the REASON he returned, DISHONEST NOODLE HEAD IDIOT!
Thanks A Million!
Will be in touch!
Be well and prosper...
The Weill Cornell Connection
Isn't it interesting several pharmaceutical companies have a history of forming partnerships with The Weill Cornell University Medical College that aims to speed the drug discovery process of new clinical treatments. Not only this, they're supported by The Bill & Melinda Gates Foundation at the tune of at least $20M.
PROOF:
https://news.weill.cornell.edu/news/2012/06/weill-cornell-partners-with-pharmaceutical-companies-and-academic-researchers-to-speed-tuberculosis
This is what the Canary Acquisition is based on, i.e. to license their technology in the scope of the drug discovery process that's going to required $50M funding.
If this acquisition goes through, it will instantly result in a fundamental change in RGBP's Market Profile and put them on the Fast Track for advancing toward market for new clinical therapeutics based in their I.P. Portfolio which is the EXACT reason Dr. Koos made it his business this year to aggressively ACTIVATE several of his expired Patents.
IS THIS MAKING SENSE YET??? IF NOT, IT SHOULD!
Let's just hope that Acquisition goes through.
Be well and prosper...
That's My Perspective As Well!
I strongly believe the $50M funding support for the Canary Acquisition from a BIG SHOT PARTNER is a far gone conclusion, and no doubt insiders are aware of it.
I could be wrong BUT we will find out real soon!
Because of this I fully expect RGBP's PPS to substantially RISE going into the New Year, with several pull backs from profit taking along the way, BUT with a steady UPWARD Trend!
If and when the Canary Acquisition occurs, that will result in a FUNDAMENTAL CHANGE IN THIS COMPANY...INSTANTLY!!
RGBP will in effect be an "all new" Company!
If anyone has done their DD on the Canary Acquisition they will learn that this represents a direct partnership with the Weill Cornell University Medical School that's a center for fast tracking the development of therapeutics that dozens of Big Pharmas have participated in AND it is supported by The Bill & Melinda Gates Foundation.
Everyone can do their own DD on this...I did mine the moment I heard of this and I'm thoroughly convinced this is a done deal AND that Dr. Koos has some serious clout that goes along with his serious Disruptive Biotechnology Patents that are the subject of that proposed Acquisition!
OPINION ONLY!
RGBP UP 44.24%
PROOF
LOW 0.0106
HIGH 0.0153
= 44.24% INCREASE!
At the time of this Post it's UP 28.45%
Cheers!
Well Said!
That's just it, the resident BUM makes EVERYTHING UP!
Sounds Very Positive
There are very few people here who give this man much credit for all the things he has done for this company over the past 9 months starting at the end of March this year and that's very unfortunate. He has shown amazing dedication toward doing everything he can to put this company on its feet and move forward with great things, and I don't expect the naysayers to agree.
There are many positive transformative things Koos has accomplished to date evidence by his 40 SEC Filings averaging 4 per month for 9 months.
At some point this is going to pay off, but how soon is anyone's guess.
Have a bless New Year.
Hello There!
Great to hear from you! Think about you often.
I will do just that this weekend now that Koos has broken his silence today and came out with a public EOY statement.
https://www.stocktitan.net/news/RGBP/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-hdtqswxirp5v.html
Not sure if you saw this but have a look.
I will contact you by email soon.
Have a Safe, Prosperous, and Wonderful New Year!
Best wishes
Dr. Koos Breaks Silence Today 12/30/21 With 2021 Summary...
...and forward looking statements.
https://www.stocktitan.net/news/RGBP/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-hdtqswxirp5v.html
Best Wishes to All for 2022
Be well and prosper...
Great Comprehensive PR Release Today on RGBP!
Sums up everything nicely to date!
Sure beats a blank!
https://pennystocks.today/rgbp-stock-the-biotech-stock-to-look-out-for-in-2022/
Be well and prosper...
AMEN!
GOOD ONE!
People keep comparing this to TSNP/HUMBL
HA! This is WAY out of TSNP's League by a Long Shot!
This is going to Multi-Dollars (double digit) in 2022
Easily single digit dollar by mid-year 2022 if not sooner.
KEEP WATCHING!
Float only 53M
This is a transformational company across many sectors; a re-definition of the Internet, Social Media, Web Conferencing, Gaming, and MUCH MUCH MORE!
It's the equivalent to investing in Facebook or Amazon 20 years ago, and don't be surprised IF they get Acquired by either one!
I'm just saying...
EXCELLENT!
I CONCUR 100%!
Time for Doc Koos to take a stand and kick these jokers square in the balls with steel toe boots!
Counter LawSuit is the name of that tune!
Do it TODAY and while your at it, immediately:
#1 Hire a CSO
#2- Get the Social Media up and running
#3- Update the company website
#4- Inform us of the status of the TWO (2) INDs licensed to Oncology Pharma getting funded and how soon that's going to happen? They have a deadline to get this done, don't they??
We all appreciate the amazing progress you've made over the past 9 Months with the 40+ SEC Filings in all, which is nothing short of miraculous, BUT today is a NEW DAY and it's time to get your MOJO back and kick some BUTT!
We know you got it in you, now SHOW 'EM WHO'S BOSS!!!
EXCELLENT!
Great move!
Very Informative!
Thank you for your great perspective! It all makes sense!
Guess we will just have to be patient and let everything play out!
I do get however that Koss is fully committed to the success of this company and the single best indicator of that IMO is his consistency and aggressiveness in bringing this company SEC Current along with the 40 Filings he dropped, dating back in March this year upon his return as CEO.
That's an average of at least 4 SEC Filings per month over the past 9 months that clearly reveals quite a number of important accomplishments including patent re-activations, the TWO (2) IND licensing deals with Oncology Pharma, etc., and revealing what his plans are in general moving forward,i.e. hiring a Science Officer, etc....and now the proposed Canary Acquisition.
I perceive he's accomplished quite a number of important things since his return as CEO in these 9 months all of which have been very positive.
So as far as where we are today, he's still laying a foundation for long term growth and I believe IF the Canary Acquisition comes to fruition, we will be solidly position for further growth, partnerships, etc, but it's going to take time, so patience is key here.
If I didn't perceive Koss is fully committed to the success of this company and/or he was NOT taking consistent actions to move things along, I would of bailed a long time ago.
I believe Regen has what it takes to become successful and the Innovative IPs are a big part of that and now that he has in hand the certified valuation of those IPs, a path is definitely opened for him to get licensing deals much easier and for top dollar, i.e. it's no longer subjective or speculative!
Have a great New Year.
Excellent Post on ALL Points!
Also thank you for informing me that Oncology Pharma is responsible for raising the money needed to fund those TWO (2) INDs and I might add they have a limited amount of time to do that. Do you know what the deadline date is for that? In my experience of CROs they typically don't perform raising capital to fund INDs although they're know to assist with resource funding.
Again ALL the points you made are spot on, excellent summary that brings everything to light.
Would you care to enlighten me further about what exactly is the role Canary plays if acquired by Regen? Are these people clinical research pharmacologists and/or biochemists?? Do they have expertise in taking candidate drug IPs to Turn Key IND's ready for entrance into clinical trials?? I'm not 100% certain what their exact role is.
Lastly, what applicable benefit did the consultant BRG bring to the table that benefited Regen? What exactly did they do for Regen that helped in the company's market directives?
Thank you in advance and Happy Holidays!
Be well and prosper...
Great Points....Very Sobering To Say The Least!
FACT IS WE ARE AT A CRITICAL CROSS ROAD!!
Here's my take:
Dr. Koos needs to come up with some very serious cash immediately to "GET THE SHOW ON THE ROAD!"
Relative to the Canary deal, the $50 Million funding from a key Investor is the fastest way for that to happen.
It seems that the Acquisition he suggested in his 4/27/21 8K is a far gone "not happening" conclusion although I believe he did receive bids on the company but rejected them, thus "change of plan" which is now the Canary deal.
It's important however to keep in mind that FUNDING is still required for those TWO (2) IND's licensed to Oncology Pharma for treating pancreatic & colon cancer via an mRNA vaccine. The amount of DOUGH required for that is NOT LESS than $160 Million. This and the Canary deal are mutually exclusive matters.
I don't see Oncology Pharma raising capital to fund those two (2) INDs for reason CROs don't typically raise money for clinical trials. Their role is focused on performing clinical trials utilizing their internal manpower resources and infrastructure for which they receive royalties upon commercialization of those INDs per their arrangement with Regen/KCL.
The MOMENT OF TRUTH HAS ARRIVED....
Koos needs to CRAP OR GET OFF THE TOILET!
If his Big SHOT Venture Capitalist/Deal Maker reputation holds true, then this shouldn't be a problem.
Sorry to put it this way but this is the present reality in no uncertain terms.
So based on what I'm seeing, Koos needs not less than $210 Million for both the Canary deal AND the two clinical trials to move forward.
If anyone feels I'm missing something here, please enlighten me.
Be well and prosper...
Wonder How Long It Will Take for The 53M Float to be BOUGHT!
Presently it's 58M but soon it will suddenly DROP to 53M when the CEO buys back 5M Shares before the END of this Month!
By end of January, the Float might be entirely BOUGHT! LOL!
Looking for 0.50 NEXT!
Correction!! ROAD IT UP 70% not 60%..
I spoke too soon!
UP 70% with 10,000 Shares!
Going up UP that to 50,000 Shares before end of year!
This is like buying Amazon or FB 25 YEARS AGO!!
Jumped In At Market OPEN JUST IN THE NICK OF TIME w/10,000 Shares!
Road it UP hitting 60% RISE in single trading session! LOL
CEO is likely in the process of BUYING BACK 5M Shares that will DROP the FLOAT to 53M! LOL!
This stock will easily hit $10 by June 2022 if not sooner!
The is the BEST Play in the Entire OTC, hands down!
Ever hear of an OTC with a Float of 53 Million??? HUH??
....AND it's in a HIGH MARKET CAPACITY SECTOR WITH METAVERSE that's heading to a TRILLION DOLLAR PLAY AND OWUV in right in the Middle of it all!
If so, please provide the ticker!
LOL!
Float Only 58M!
...soon it will be reduced by 5 Million likely before end of this year!
I'm ALL In!!
OTC Market Rotation "COME BACK" In Progress...
EXCELLENT POST!
Well said on ALL points as always!
Look for my post between now and this weekend. I am presently in the process of emailing a comprehensive summary of RGBP to several Big Pharma CEOs that includes Eli Lilly, as to why they should consider Acquiring this Company.
I made a very strong case for that which includes the one you made here about the Human Patent for NF2R6 that was recently licensed to Oncology Pharma for 2 INDs for treating pancreatic & colon cancer byRNA Vaccine!
My summary is a concise read not only on the company's history with all its Disruptive Biotech Patents, but more so on what Dr. Koos has accomplished over the past 9 months with a link for all his SEC filings during this period.
If anything, it will no doubt DEFINITELY get their attention!!
In the line up of the CEOs I will be emailing is Gilead Sciences who acquired Kite Pharma in 2016 for $12 Billion that I believe was motivated in part due to Kite's mRNA Vaccine IND for treating various cancers!
Be well and prosperous...
AGREED!
The mRNA Vaccine Revolution Under Way Exponentially
Excerpts from relevant articles:
Until recently most people had never even heard of mRNA Vaccines. Now scientists believe they may be the key to solving a vast array of health problems.
Last year (2020) Anna Blakney was working in a niche field of science in a lab in London. Few people outside of her scientific circles had heard of mRNA vaccines. Because none yet existed. Attendees at an annual conference talk she gave in 2019 could be counted in the tens, not hundreds. Today, she's in high demand, i.e. an Assistant Professor at the University of British Columbia, Canada, and a Science Communicator with 253,000 followers and 3.7 Million likes on Tik-Tok. She admits she was in the right place at the right time to ride a once-in-a-generation wave of scientific progress. She even gave this new era a name: "The RNAissance".
Due to the Covid-19 pandemic, many people have now heard of – and have received – an mRNA vaccine the Big Pharmas Pfizer-BioNTech and Moderna. But when Blakney started her PhD at Imperial College London in 2016, "a lot of people were skeptical whether it could work". Now, "the whole field of mRNA is just beginning to explode. It's a game changer in medicine," she says.
Blakney goes on to say "It's such a game changer it raises some very exciting questions: could mRNA vaccines prove to be a cure for cancers, HIV, tropical diseases."
Messenger ribonucleic acid, or mRNA for short, is a single-stranded molecule that carries genetic code from DNA to a cell's protein-making machinery. Without mRNA, your genetic code wouldn't be used, proteins wouldn't be made, and your body wouldn't work. If DNA is the bank card, then mRNA is the card reader.
Billions of doses of mRNA vaccines have been administered across the globe since the Covid-19 outbreak began. (Credit: Getty Images)
Billions of doses of mRNA vaccines have been administered across the globe since the Covid-19 outbreak began. (Credit: Getty Images)
CHANGE AGENTS
We know the world has to change for humanity to thrive. But what are the most promising solutions that could provide the kind of transformation we need? In a world adjusting to the recent global pandemic, Change Agents examines innovations and technologies that could make our planet a better, healthier place to live.
Once a virus is inside our cells, it releases its own RNA, tricking our hijacked cells into spewing out copies of the virus – in the form of viral proteins – that compromise our immune system. Traditional vaccines work by injecting inactivated virus proteins called antigens, which stimulate the body's immune system to recognize the virus when it reappears.
The genius of mRNA vaccines is there's no need to inject the antigen itself. Instead, these vaccines use the genetic sequence or "code" of the antigen translated into mRNA. It's a ghost of the real thing, fooling the body into creating very real antibodies. The artificial mRNA itself then disappears, degraded by the body's natural defenses including enzymes that break it down, leaving us with only the antibodies.
It's therefore safer to produce more quickly and cheaply, compared with traditional vaccines. You no longer need huge bio-secure labs growing deadly viruses inside millions of chicken eggs. Instead, just one lab can sequence the proteins of the antigen and email it around the world. With that information a lab could make "a million doses of mRNA in a single 100ml test tube," says Blakney.
We've now seen that process play out in real time. On 10 January 2020, Zhang Yongzhen, a Professor at the Chinese Center for Disease Control and Prevention in Beijing, sequenced the genome for Covid-19 and published it the next day. Covid-19 was declared a pandemic by the World Health Organization (WHO) on March 11th. On March 16th, using Zhang's sequence, the first mRNA vaccine began Phase 1 Clinical Trials.
The US Food and Drug Administration approved the Pfizer-BioNTech Covid-19 vaccine on December 11, 2020, making history as not only the first ever mRNA vaccine approved for humans, but also the first to have a 95% efficacy rate in clinical trials.
Approval of the Moderna mRNA vaccine followed close behind on December 18, 2020. The previous title holder for "fastest ever vaccine", i.e. the Mumps Vaccine, in comparison took four years. The Moderna & Pfizer–BioNTech Vaccines took just 11 Months.
There weren't many people in the mRNA therapeutics world who would have imagined a 95% initial efficacy rate – Kathryn Whitehead said.
The theory behind the mRNA vaccine was pioneered by University of Pennsylvania scientists Katalin Karikó and Drew Weissman, who both recently received the 2021 Lasker Award, America's top biomedical research prize. In 2019 however, mainstream mRNA vaccines development and application were believed to be at least five years away.
The pandemic fast-forwarded this field of medicine by half a decade. Kathryn Whitehead, an associate professor of chemical engineering and biomedical engineering at Carnegie Mellon University, and a key collaborator of Weissman and Karikó admits, "there weren't many people in the mRNA therapeutics world who would have imagined 95% initial efficacy rates in this emergency scenario".
But now the possibilities are seemingly endless. As Blakney puts it: "Now it's like, OK, so since it's worked for a viral glyco-protein, what other vaccines can we make with it? And what can we do beyond that?"
The pioneering work of Katalin Kariko and Drew Weissman on mRNA paved the way for the Pfizer and Moderna Covid-19 Vaccines.
At the University of Rochester, Dragony Fu, associate professor, department of biology, received expedited funding for his laboratory from the National Science Foundation to research RNA proteins. If we are currently witnessing mRNA vaccine 1.0 for Covid-19, then 2.0 will address two further categories of disease, says Fu: "one is pathogens, like Sars, but you can apply this technology to other foreign invaders such as HIV.
Already before Covid, companies were in development making mRNA vaccines against HIV." He also cites Zika, herpes and malarial parasites in the pathogens camp.
"The other category is autoimmune diseases," he says. "That is intriguing because it's verging beyond the very strict definition of a vaccine." Fu says the future could involve mRNA "treatments", for example to reduce inflammation. "In theory, that opens up so many possibilities," he says.
Yizhou Dong, associate professor of pharmaceutics and pharmacology Ohio State University, specializes in little balls of fat, or lipids, needed to house the mRNA and safely deliver it to the cells without being immediately destroyed by our body. Lipids have been described as the "unsung hero" – without lipid delivery being finally perfected and approved in 2018, there would have been no Covid-19 mRNA vaccines by 2020.
Before Covid-19, there were many research studies looking at broader applications of combining this new lipid delivery technique with mRNA Dong says, including genetic disorders, cancer immuno-therapy, infectious diseases and bacterial infections. "As long as you have the antigen and can sequence the protein, theoretically it should work".
Thanks to the combined breakthrough in lipid delivery and mRNA technology, vaccines and treatments in development include Translate Bio's mRNA therapy's for cystic fibrosis and multiple sclerosis; Gritstone Oncology and Gilead Sciences' mRNA vaccine for HIV; Arcturus Therapeutics' therapies for cystic fibrosis and heart disease; and German start-up Ethris, with Astra-Zeneca, are developing mRNA therapies for severe pulmonary diseases and asthma.
Zika is one of many diseases that there may be an mRNA vaccine for in the future. Solutions for tropical diseases are being explored too. Moderna are close to phase two (out of three) in clinical mRNA vaccine trials for both Zika and Chikungunya. Both are described as "neglected", so-called because they effect the poorest populations of the world and do not receive adequate research and funding. The speed and cost of mRNA vaccines could change that paradigm and signal the end of neglected tropical diseases.
Perhaps the first new mRNA vaccine to hit our shelves, however, will be for a more familiar foe – the flu. Influenza viruses are responsible for an estimated 290,000–650,000 deaths annually worldwide. "We're most likely to see mRNA vaccines against influenza in the near future," says Whitehead. "These mRNA vaccines have been in development for years, and clinical trials to date have been encouraging. There are currently five clinical trials for Influenza A, including one in phase two". This could be just in time.
Paul Hunter, a professor of health protection at the University of East Anglia in the UK who also consults for the WHO, has warned that some countries may be due an influenza epidemic that could lead to more fatalities than Covid-19.
Several pharmaceutical companies are also pursuing mRNA vaccines for cancer. "Cancer cells will often have certain surface markers that the rest of the cells in your body don't have," says Blakney. “You can train your immune system to recognize and kill those cells, just like you can train your immune system to recognize and kill a virus: it's the same idea, you just figure out what proteins are on the surface of your tumor cells and use that as a vaccine".
The idea of patient-specific individualized medicine has been a promising prospect for years – this could be another door opening wide by mRNA vaccine technology, according to Blakney.
In theory, "they take out your tumor, sequence it, see what's on the surface of it, and then make a vaccine specifically for you".
From cancer to HIV, tropical diseases to antibiotic resistance, scientists believe there could be a huge range of mRNA vaccine solutions.
If treatments for cancer, HIV, and tropical disease are coming along with mRNA 2.0, then what could be even further down the line with 3.0?
One area of concern for modern medicine is antibiotic resistance. "Potentially you could envision actually making a vaccine against a bacterial antigen such as C. Difficile or some of the others difficult to treat bacterias," says Blakney. There are no trials yet, but scientific journals such as Frontiers have explored this idea.
There's also potential for more general commercial health and well being applications. For example, Fu suggests that lactose intolerance – that affects hundred of millions of people of Asian origin, and an estimated 68% of the global population – could one day be targeted: "I'm missing the protein that allows me to break down lactose. He goes on to say that in the future you could develop a way of delivering the message that mRNA vaccines will make the protein that breaks down lactose and it's not life threatening, but I could imagine it being a billion-dollar industry."
At Ohio State, Dong has even run a successful mouse trial targeting cholesterol. People with high levels of the protein PCSK9 tend to have high cholesterol and develop heart disease early. "We noticed that after one treatment [in mice], we can reduce the PCSK9 protein level by over 95%.
That's definitely a very important research direction." At least one biotech company is planning a clinical trial using mRNA to inhibit PCSK9 according to Dong. You could take scores of different flavors… a cocktail of mRNAs that make different proteins selective for your particular need – Dragony Fu
All this raises the question: could mRNA therapeutics give us almost superhuman immunity? Already Covid-19 mRNA vaccines lead some people to produce very high levels of antibodies, able to neutralize several variants of Covid-19 at once.
There's also the potential to mix various mRNA vaccines together into a single health booster vaccine, which could ward off cancers and viruses at the same time.
Both Moderna and Novavax already have combined Covid-19 and flu vaccines in development. Self-amplifying mRNA vaccines may ultimately prevail. They reduce the need for painful boosters.
However questions remain around mRNA vaccines. Currently we need regular booster shots – and these shots tend to hurt, sometimes with fatiguing side effects. At the time of writing, we are less than a year into real-world use.
Anaphylactic reactions (albeit with no deaths) have been observed in approximately 2 to 5 people per million vaccinated in the United States: slightly higher, 4.7 per million, with the Pfizer–BioNTech vaccine compared to 2.5 per million vaccinations from the Moderna vaccine. According to one analysis, while still low, this is 11 times higher than with the flu vaccine.
"We're still working to understand how long the antibody response lasts for as well as the cellular response," says Blakney. "There's good indication now that you do get a really good memory T-cell response from the mRNA vaccines, but since these trials are a year and a half old in most cases we're still understanding how long that immunity lasts." Furthermore, most people, "don't really want to get multiple vaccines every year that knock you out for three days afterwards".
Blakney's lab at UBC is however working on an answer: sa-mRNA, or self-amplifying mRNA. It has the same structural components as normal mRNA, except once inside a cell it can make copies of itself. "This is advantageous because it allows using a much lower dose about 100X less saRNA compared to mRNA," says Blakney.
This means more bang for your buck, and less arm pain. In a tortoise versus hare race, mRNA vaccines may have run ahead to combat Covid-19, but sa-mRNA may win out in the end – and indeed has just received $195M backing from Astra-Zeneca.
Fu, Dong, Whitehead and Blakney continue to ride the wave of mRNA as it's transitioning into expanded applications for treating infectious diseases and cancers.
RGBP Is A FAR GREATER Fit Than ENZC And Here's Why!
# 1 RGBP has (24+) Disruptive Biotech Patents worth $$ BILLIONS; ENZC has only two (2).
https://patents.google.com/?inventor=David+Koos&sort=new
https://patents.justia.com/assignee/regen-biopharma-inc
https://www.otcmarkets.com/filing/html?id=15088630&guid=dk3wkKwg3iFaJth
# 2 Eli Lilly had prior collaborative arrangement with RGBP with joint I.P. claim on NR2F6 for developing an mRNA Cancer Vaccine
https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/
# 3 Eli Lilly-Curevac 2017 Partnership to develop mRNA Cancer Vaccine FAILED Ending June 2020 due to Curevac's faulty research data. Lilly lost $100 Million in shared development costs. Merger/Acquisition with RGBP is the shortest path to getting back on track!
# 4 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine; The Future of Medicine
https://www.aamc.org/news-insights/mrna-technology-promises-revolutionize-future-vaccines-and-treatments-cancer-infectious-diseases
# 5 RGBP is in league with Big Pharmas developing mRNA Cancer Vaccines that Eli Lilly clearly wants to be included in, especially in the wake of their failed relationship with Curevac. It is a Trillion Dollar Market!
https://www.ventureradar.com/keyword/Cancer%20Vaccines
# 6 FDA Patent Approval
https://newsinvasion24.com/regen-biopharma-inc-otcmkts-rgbp-gets-approval-for-cancer-vaccine-patent/
# 7 Partnership:Oncology Pharma Paid $1M for Patent Licensing; will now Post Quarterly Revenues for 15 Years
# 8 Certification Audit of RGBP by BRG completed 11/15/21. This is indicative of an Industry Standard Merger/Acquisition
#9 On 4/27/21 CEO files Acquisition Intent with 8K
https://www.otcmarkets.com/filing/conv_pdf?id=14894907&guid=55ywkew26hwfJth
Opinion ONLY
Be well and prosper...
You Mean RGBP
Well Said!
Great Analysis!
Be well and prosper...